Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From DaVita Labs

Ozempic Cuts Kidney Risk By 24%

But Novo’s blockbuster lags established drugs in diabetic kidney disease patients, and will probably be regarded as an adjunct.

Clinical Trials Metabolic Disorders

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.

Medtech 100 Commercial

The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease

The Danish giant’s GLP-1 agonist blockbuster is effective against diabetes, obesity and cardiovascular disease. Now kidney disease can be added to the list after a Phase III trial was halted for efficacy.

Renal Clinical Trials

News We’re Watching: Abbott FreeStyle Libre Recall, Medtronic Partners With DaVita, Free SBOM Software

This week, Abbott announced a class I recall of several glucose management systems. Additionally, Medtronic announced partnerships with DaVita and Qure.Ai; Heartflow closed a funding round; and BiVacor readies for artificial heart trials.

Commercial Policy
See All

Company Information

  • Industry
  • Laboratory Testing Services
  • Services